[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Design Therapeutics Inc (DSGN)

Design Therapeutics Inc (DSGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 735,743
  • Shares Outstanding, K 62,457
  • Annual Sales, $ 0 K
  • Annual Income, $ -69,790 K
  • EBIT $ -79 M
  • EBITDA $ -81 M
  • 60-Month Beta 1.58
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.33

Options Overview Details

View History
  • Implied Volatility 155.74% (-15.22%)
  • Historical Volatility 69.63%
  • IV Percentile 38%
  • IV Rank 17.74%
  • IV High 469.08% on 11/13/25
  • IV Low 88.15% on 08/18/25
  • Expected Move (DTE 25) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 33
  • Volume Avg (30-Day) 142
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 36,566
  • Open Int (30-Day) 36,593
  • Expected Range 11.78 to 11.78

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.36
  • Number of Estimates 3
  • High Estimate $-0.29
  • Low Estimate $-0.46
  • Prior Year $-0.34
  • Growth Rate Est. (year over year) -5.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.37 +3.63%
on 07/24/26
15.86 -25.73%
on 07/06/26
-2.00 (-14.51%)
since 06/24/26
3-Month
9.87 +19.35%
on 06/02/26
17.25 -31.71%
on 04/29/26
-0.75 (-5.99%)
since 04/24/26
52-Week
3.76 +213.30%
on 07/31/25
17.25 -31.71%
on 04/29/26
+7.74 (+191.58%)
since 07/24/25

Most Recent Stories

More News
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1

GeneTAC ® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1 CARLSBAD, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Design...

DSGN : 11.78 (+1.29%)
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference

CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today...

DSGN : 11.78 (+1.29%)
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia

DT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endogenous frataxin mRNA and protein after four weeks of intravenous dosing DT-216P2 generally well-tolerated...

DSGN : 11.78 (+1.29%)
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026

CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will...

DSGN : 11.78 (+1.29%)
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates

Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapiro, M.D., Appointed to Board of Directors, Strengthening Clinical and Regulatory Expertise Cash...

DSGN : 11.78 (+1.29%)
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates

Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026 Cash and Securities of $219.8 Million as of Year-End Supports Ongoing...

DSGN : 11.78 (+1.29%)
Design Therapeutics to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today...

DSGN : 11.78 (+1.29%)
Design Therapeutics to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today...

DSGN : 11.78 (+1.29%)
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results

Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1)  Trials of DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs...

DSGN : 11.78 (+1.29%)
Design Therapeutics Appoints Justin Gover to Board of Directors

CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases,...

CMPS : 11.26 (-3.84%)
DSGN : 11.78 (+1.29%)
XENE : 65.42 (unch)

Business Summary

Design Therapeutics Inc. is a biotechnology company. It involved in developing a platform of gene targeted chimera small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions. Design Therapeutics Inc. is based in CARLSBAD, Calif.

See More

Key Turning Points

3rd Resistance Point 12.83
2nd Resistance Point 12.46
1st Resistance Point 12.12
Last Price 11.78
1st Support Level 11.40
2nd Support Level 11.03
3rd Support Level 10.69

See More

52-Week High 17.25
Fibonacci 61.8% 12.10
Last Price 11.78
Fibonacci 50% 10.51
Fibonacci 38.2% 8.91
52-Week Low 3.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.